Pharmaceutical Journal
employs a group of people who are passionate about and dedicated to medical publishing, and who are experienced in this specialised field. Our staff consists of medical doctors, medical copyeditors, advertising and branding consultants, graphic designers and web, distribution and production coordinators.
Sunday, December 6, 2015
Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. About Lamictal (Lamotrigine) without prescription (NASDAQ: DYAX) today announced a poster presentation
describing preclinical data for DX-4012, the Company’s fully human
monoclonal antibody to activated Factor XII (Factor XIIa), was presented
at the 57th American Society of Hematology (ASH) Annual Meeting and
Exposition taking place December 5-8, 2015 in Orlando, Florida.
“The poster presented at ASH this year describes how DX-4012
demonstrated anti-thrombotic activity in various animal models, without
evidence of increased bleeding risk,” said Burt Adelman M.D., Chief
Medical Officer and Executive Vice President of Research and Development
at Dyax. Motilium (Domperidone) with no Rx “These data are a significant achievement for the Dyax research
team and indicate that DX-4012, either as a monoclonal antibody or as a
component of a bispecific antibody, shows potential as a novel
antithrombotic therapy.”
A summary of data presented is below:
Title: Discovery and Characterization of a Highly Specific
Antibody Inhibitor of Factor XIIa (FXIIa), and the Subsequent Generation
of Factor XIIa/Plasma Kallikrein (PK) Bispecific AntibodyDate
and time: Sunday, December 6, 2015 from 6:00 – 8:00pm ETAbstract
#: 83101Session: 321. About Cordarone (Amiodarone) with free Rx Blood Coagulation and
Fibrinolytic Factors: Poster IILocation: Hall A, Level 2Summary:
In this report, investigators describe the discovery and preclinical
evaluation of DX-4012 as a highly selective and potent inhibitor of
FXIIa. Intalith without Rx DX-4012 inhibits the proteolytic activity of FXIIa with an
apparent Ki of ~15 pM, and does not inhibit closely related sequence
homologs or other coagulation factors at concentrations up to 1 µM. Buy Cardarone (Amiodarone) with no Rx When
tested at 1 µM in human plasma, DX-4012 prolonged the activated partial
thromboplastin time (aPTT) 3.4-fold, with no effect on the prothrombin
time (PT). Buy Horsetail online In a baboon arteriovenous shunt model of thrombosis, a single
10mg/kg intravenous infusion reduced platelet and fibrin deposition up
to 192 hours after administration, demonstrating an antithrombotic
effect with no increased risk of bleeding.
About DX-4012Discovered using Dyax’s proprietary phage
display technology platform, DX-4012 is a fully human monoclonal
antibody inhibitor of FXIIa. http://asthmareview.wordpress.com Preclinical data indicate that DX-4012
shows potential as a novel antithrombotic therapy. Current areas of
interest for this investigational product candidate are extracorporeal
membrane oxygenation (ECMO), lupus anticoagulant syndrome and as a
potential alternative treatment for patients who require prolonged
antithrombotic therapy but cannot tolerate conventional anticoagulation.
About DyaxDyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for unmet
medical needs. The Company is developing DX-2930,
a fully human monoclonal antibody, for the prevention of HAE attacks.
Additionally, Dyax markets KALBITOR®
(ecallantide) for the treatment of acute attacks of HAE in patients
12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax s proprietary phage
display technology. Dyax has broadly licensed this technology under its
Licensing
and Funded Research Portfolio (LFRP). The current portfolio includes
two FDA approved products and multiple product candidates in various
stages of clinical development for which the Company is eligible to
receive future milestones and royalties.
For additional information about Dyax, please visit .dyax.com.
For additional information about KALBITOR, including full prescribing
information, please visit .KALBITOR.com.
DisclaimerThe press release contains forward-looking
statements, including statements regarding the prospects for an
investigational product, DX-4012. Statements that are not historical
facts are based on Dyax’s current expectations, beliefs, assumptions,
estimates, forecasts and projections about the industry and markets in
which Dyax competes. The statements contained in this press release are
not guarantees of future performance and involve certain risks,
uncertainties and assumptions that are difficult to predict. Therefore,
actual outcomes and results may differ materially from what is expressed
in such forward-looking statements. There are many factors that could
cause actual results to differ materially from those in these
forward-looking statements. These factors include the following: the
results from pre-clinical studies may not be predictive of the results
or success of future clinical trials that will be required to permit
application for regulatory approval of DX-4012; even if DX-4012
progresses through clinical trials and gains regulatory approval, it may
not gain market acceptance; others may develop technologies or products
superior to DX-4012; Dyax is dependent on the expertise, effort,
priorities and contractual obligations of third parties in the
manufacture, quality control, storage and clinical development of
DX-4012; the costs of prosecuting, maintaining, defending and enforcing
our patents and other intellectual property rights; the overall
condition of the financial markets; and a variety of other risks common
to our industry; changing requirements and costs associated with Dyax s
planned research and development activities; the uncertainty of patent
and intellectual property protection; and other risk factors described
or referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual
Report on Form 10-K and other periodic reports filed with the Securities
and Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements, except
as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
Subscribe to:
Posts (Atom)